

A new US patent granted to Proteus for its acylations enzymatic technology in USA

Nîmes, France - March 10, 2016 –

Industrial biotechnology firm Proteus, a member of PCAS Group, has announced the issuance of its patent US9,145,570B2 titled "« Enzymatic acylation method using an acylphosphonate donor »". *"This newly issued patent is the US counterpart of our international filing WO 2012013765. This patent strengthens our intellectual property position and our global leadership in the field of biocatalysis"* said Isabelle Lellouche, patent counsel, in charge of intellectual property at Proteus.

The invention relates to an enzymatic process acylation with acylphosphonate donor to produce various organic compounds such as active pharmaceutical intermediates or ingredients, products or feedstock for the flavor and fragrance industry, or any other commodity products.

This technology has been successfully used to develop an acylating method avoiding many stages of protection / deprotection necessary via conventional chemical methods of acylation. *"In fact, biocatalysis coupled to specific acyl phosphate donor allow an atom economy, a fabulous gain of time and a costs reduction versus traditional chemistry."*Said Juliette Martin, Proteus CEO. *"This patent strengthens our dominant position and our expertise in biocatalysis, allowing our headquarter PCAS to maintain its leadership in fine chemicals and pharmaceuticals."*

About Proteus, member of PCAS group

Proteus (www.proteus.fr) is a biotech company, specialized in developing and implementing sustainable industrial processes using enzymes and microbial strains. To fulfill this mission, Proteus has a portfolio of proprietary technologies including an exclusive collection of microbial biodiversity, technologies for enzymes engineering and microbial strains optimization, as well as a platform for enzymes production and formulation making possible their industrial use. Integrated in the fine chemicals group PCAS (www.PCAS.com), Proteus also benefits of the capabilities and industry expertise of the group.

About PCAS

PCAS specialises in the development and production of complex molecules for Life Sciences and Innovative Technologies. With 7% of its turnover dedicated to R&D and a wide international presence, PCAS is the preferred industrial partner of market-leading major global groups. The company offers a growing range of proprietary products and solutions in leading-edge segments, and also includes two subsidiaries with very strong potential: Protéus in biotechnology and Enersens in high-performance insulation. With a particularly high standard of performance, PCAS achieved net sales of 179,1 M€ in 2015 and employs nearly 900 people in six countries. For more information on PCAS: www.pcas.com

Contact

Protéus S.A.
email : info@proteus.fr
www.proteus.fr